Reading EQ? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track EQ free→Reading EQ? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track EQ free→QuarterlyIQ Insights · EQ
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
of this Current Report on 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, regardles…
of this Current Report on 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, regardles…
The Company expects to use the net proceeds from the Closing of the Private Placement, together with the Company’s existing cash and cash equivalents, to fund the development of EQ504, as well as for working capital and other general corporate purposes. The securities described above under
Entry into a Material Definitive Agreement. Securities Purchase Agreement On March 11, 2026, Equillium, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with RA Capital Healthcare Fund, L.P. (the “Investor”), pursuant to which the Company agreed to sell and issue shares (“Shares”) of the Company’s common stock, par value $0.0001 (“Common Stock”), and a pre-funded warrant to purchase shares of Common Stock (“Warrant Shares”),…
of this Current Report on 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, regardles…
Changes in Registrant's Certifying Accountant. As previously disclosed in the Original Form 8-K, the audit committee of the Company's Board of Directors previously approved the appointment of Crowe LLP (“Crowe”), an independent registered public accounting firm, to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The Company’s engagement of Crowe remained subject to the completion of Crowe’s client acceptance procedures and exe…
Other Events. On September 30, 2025 (the “Termination Date”), the Company entered into a termination agreement with Biocon Limited (“Biocon” and the agreement, the “Termination Agreement”) pursuant to which the Company and Biocon terminated that certain (i) collaboration and license agreement with Biocon, dated May 22, 2017, as amended September 28, 2018, April 22, 2019, December 10, 2019, and April 14, 2021 (the “Biocon License”), (ii) the Memorandum of Understanding dated April 7, 2022 (the…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) Resignation of Directors On September 30, 2025, each of Stephen Connelly, Ph.D. and Bala Manian, Ph.D. tendered his resignation from the Board, effective October 1, 2025 (the “Effective Date”). Additionally, Dr. Manian tendered his resignation from the Audit Committee and from the Compensation Committee of the Board (the “Compensation Committee…
Changes in Registrant’s Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm On September 30, 2025, the Audit Committee (the “Audit Committee”) of the Board of Directors (the “Board”) of Equillium, Inc. (the “Company”) approved dismissal of KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm, with such dismissal to become effective on September 30, 2025. KPMG’s audit reports on the Company’s consolidated financial statements as of…
Other Events. On September 19, 2025, Equillium, Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) with the Securities and Exchange Commission (the “SEC”) for the offer and sale of shares of its common stock, par value $0.0001 per share, having an aggregate offering price of up to $75,000,000 (the “Shares”), pursuant to that certain Open Market Sale Agreement, dated October 5, 2023, as amended August 3, 2025, by and between the Company and LifeSci Capital LLC (th…
of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing. Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements wit…
The Company expects to use the net proceeds from the Initial Closing of the Private Placement, together with the Company’s existing cash and cash equivalents, to fund the development of EQ504, as well as for working capital and other general corporate purposes. The securities described above under
Entry into a Material Definitive Agreement. Securities Purchase Agreement On August 10, 2025, Equillium, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and accredited investors (the “Investors”), pursuant to which the Company agreed to sell and issue shares (“Shares”) of the Company’s common stock, par value $0.0001 (“Common Stock”), and pre-funded warrants to purchase shares of Common Stock (“Wa…
Entry into a Material Definitive Agreement On August 3, 2025, Equillium, Inc. (“Equillium” or the “Company”) entered into Amendment No. 1 (the “Amendment”) to the Open Market Sale Agreement SM , dated October 8, 2023, by and between the Company and Jefferies LLC (the “ATM Agreement”), pursuant to which Jefferies LLC was replaced by LifeSci Capital LLC as the sales agent under the ATM Agreement. The foregoing description of the material terms of the Amendment is not complete and is qualified i…
Results of Operations and Financial Condition On August 4, 2025, the Company issued a press release (the “Press Release”) announcing the Company had cash and cash equivalents totaling approximately $11.5 million as of June 30, 2025. A copy of the Press Release is furnished as Exhibit 99.1 to this Form 8-K. The preliminary results set forth above are unaudited, are based on management’s initial review of the Company’s results for the quarter ended June 30, 2025, and are subject to revision bas…
Other Events The Company has amended its investment policy to authorize the purchase of cryptocurrency as a treasury reserve strategy. As of the filing of this Current Report on Form 8-K, the Company has not purchased any cryptocurrency in furtherance of this strategy, but it intends to actively pursue opportunities to give effect to this strategy and expects to provide updates on this strategy during the third quarter of 2025. In parallel with the addition of the cryptocurrency treasury stra…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on December 13, 2024, Equillium, Inc. (the “ Company ” ) received a notice from The Nasdaq Stock Market LLC (“ Nasdaq ”) that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the minimum bid price of the Company’s common stock had been below $1.00 per share for the previous 30 consecutive business days (the “ Minimum Bid Price Requirement ”…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) On May 21, 2025, Equillium, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). As described in
Results of Operations and Financial Condition. On April 24, 2025, Equillium, Inc. (the “Company”) announced that its estimated cash, cash equivalents and short-term investments as of March 31, 2025 was approximately $14.5 million in the press release attached hereto as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated by reference. The Company’s actual financial statements as of and for the quarter ended March 31, 2025 are not yet available. The actual amounts that the Co…
of this Current Report on 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, regardles…
Other Events. On February 6, 2025, Equillium, Inc. (the “Company”) and Biocon Limited (“Biocon”) announced topline data from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ulcerative colitis (“UC”). The double-blinded, placebo- and active-controlled Phase 2 clinical study evaluated the safety and efficacy of itolizumab in biologic-naïve patients with moderate to severe active UC. A total of 90 patients were randomized 1:1:1 to receive itolizumab (fixed dose of…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.